<?xml version="1.0" encoding="UTF-8"?>
<p>Besides the pharmacologic interventions, vaccines are an effective approach for the prevention and prophylaxis of SARS-CoV-2 [
 <xref rid="B128-viruses-12-01039" ref-type="bibr">128</xref>]. The main strategies used in the development of a coronavirus vaccine involve the spike protein. Currently, there are thirty-one candidate vaccines under clinical evaluation, and six candidate vaccines have been pursued in Phase 3 clinical trials. These candidate vaccines include several standard platforms of inactivated vaccines, live-attenuated vaccines, and protein subunit vaccines, as well as some novel approaches, such as DNA-and RNA-based platforms, and replicating and nonreplicating vector platforms [
 <xref rid="B129-viruses-12-01039" ref-type="bibr">129</xref>].
</p>
